EL7.AI
StocksUpdated•Originally published 16 April 2026•Updated 16 April 2026•
1 min read

Daiichi Sankyo and Wayfinder Biosciences Advance Neurodegeneration Research to Phase 2

Key Facts

1Wayfinder Biosciences and Daiichi Sankyo have advanced their research collaboration to the second phase.
2The initial phase successfully focused on discovering novel RNA-targeting small molecules for a key neurodegeneration target.

Wayfinder Biosciences and Daiichi Sankyo have advanced their research collaboration to Phase 2 following successful results in discovering RNA-targeting small molecules for neurodegeneration. In a separate strategic move, Daiichi Sankyo Research Institute Boston has entered into a new research collaboration with Interna Therapeutics to evaluate its Molecular Nano Motor (MNM) technology. This new partnership aims to integrate MNM molecules with specialized targeting approaches to enhance intracellular delivery and overall therapeutic performance. Interna Therapeutics is a clinical-stage biotechnology company based in Petach Tikva, Israel, specializing in advanced delivery platforms. These combined developments underscore Daiichi Sankyo's aggressive expansion of its neurology pipeline through diverse technological partnerships. While the Wayfinder project focuses on RNA targets, the Interna collaboration seeks to optimize drug delivery mechanisms for future therapies.